Myeloid-derived suppressor cells and the efficacy of CD8+ T-cell immunotherapy

被引：6
|
作者：
Lesokhin, Alexander M. [1 ]
Merghoub, Taha [1 ]
Wolchok, Jedd D. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
ONCOIMMUNOLOGY | 2013年 / 2卷 / 02期
关键词：
CCR2; myeloid derived suppressor cells; GM-CSF; immunotherapy; adoptive T-cell transfer; ANTIGEN; INFILTRATION; CANCER;
D O I：
10.4161/onci.22764
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful adjunct to available immunotherapeutic strategies against cancer.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer
    Arina, Ainhoa
    ONCOIMMUNOLOGY, 2014, 3 (04)
  • [22] Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
    Wang, Yufei
    Jia, Anna
    Bi, Yujing
    Wang, Yuexin
    Yang, Qiuli
    Cao, Yejin
    Li, Yan
    Liu, Guangwei
    CANCERS, 2020, 12 (09) : 1 - 24
  • [23] Role of myeloid-derived suppressor cells in tumor immunotherapy
    Martin, Francois
    Apetoh, Lionel
    Ghiringhelli, Francois
    IMMUNOTHERAPY, 2012, 4 (01) : 43 - 57
  • [24] Targeting myeloid-derived suppressor cells for cancer immunotherapy
    Yijun Liu
    Guowei Wei
    Wesley A. Cheng
    Zhenyuan Dong
    Han Sun
    Vincent Y. Lee
    Soung-Chul Cha
    D. Lynne Smith
    Larry W. Kwak
    Hong Qin
    Cancer Immunology, Immunotherapy, 2018, 67 : 1181 - 1195
  • [25] Targeting myeloid-derived suppressor cells for cancer immunotherapy
    Liu, Yijun
    Wei, Guowei
    Cheng, Wesley A.
    Dong, Zhenyuan
    Sun, Han
    Lee, Vincent Y.
    Cha, Soung-Chul
    Smith, D. Lynne
    Kwak, Larry W.
    Qin, Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (08) : 1181 - 1195
  • [26] Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
    Hao, Zhaonian
    Li, Ruyuan
    Wang, Yuanyuan
    Li, Shuangying
    Hong, Zhenya
    Han, Zhiqiang
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [27] Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
    Zhaonian Hao
    Ruyuan Li
    Yuanyuan Wang
    Shuangying Li
    Zhenya Hong
    Zhiqiang Han
    Biomarker Research, 9
  • [28] Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth
    Hongyun Zhao
    Da Teng
    Lifeng Yang
    Xincheng Xu
    Jiajia Chen
    Tengjia Jiang
    Austin Y. Feng
    Yaqing Zhang
    Dennie T. Frederick
    Lei Gu
    Li Cai
    John M. Asara
    Marina Pasca di Magliano
    Genevieve M. Boland
    Keith T. Flaherty
    Kenneth D. Swanson
    David Liu
    Joshua D. Rabinowitz
    Bin Zheng
    Nature Metabolism, 2022, 4 : 1660 - 1673
  • [29] Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis
    Davila, E
    Kang, YM
    Park, YW
    Sawai, H
    He, XW
    Pryshchep, S
    Goronzy, JJ
    Weyand, CM
    JOURNAL OF IMMUNOLOGY, 2005, 174 (11): : 7292 - 7301
  • [30] Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth
    Zhao, Hongyun
    Teng, Da
    Yang, Lifeng
    Xu, Xincheng
    Chen, Jiajia
    Jiang, Tengjia
    Feng, Austin Y.
    Zhang, Yaqing
    Frederick, Dennie T.
    Gu, Lei
    Cai, Li
    Asara, John M.
    di Magliano, Marina Pasca
    Boland, Genevieve M.
    Flaherty, Keith T.
    Swanson, Kenneth D.
    Liu, David
    Rabinowitz, Joshua D.
    Zheng, Bin
    NATURE METABOLISM, 2022, 4 (12) : 1660 - +
12345